H5N1 influenza VLP vaccine

The H5N1 influenza VLP vaccine is a vaccine candidate developed by Novavax, designed to combat the H5N1 avian influenza virus. It utilizes virus-like particle (VLP) technology, where non-infectious particles mimic the external structure of the virus, including key antigens like hemagglutinin (HA) and neuraminidase (NA), but lack the genetic material to replicate. This design aims to induce a robust immune response in the recipient, thereby providing protection against H5N1 infection and contributing to pandemic preparedness. Novavax's candidate specifically leverages recombinant, protein-based nanoparticle technology and its Matrix-M® adjuvant to enhance immunogenicity.